FibroGen Inc

FibroGen is a privately-held biotechnology company focused on the discovery, development, and commercializaiton of therapeutic agents for treatment of fibrosis, anemia, cancer and other serious unmet medical needs. FibroGen's FG-3019 fully human monoclonal antibody is in clinical developoment for treatment of idiopathic pulmonary fibrosis and other proliferative diseases, including pancreatic cancer and liver fibrosis. Roxadustat (FG-4592), FibroGen's small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydraxylase, is currenlty in clinical developement for the treatment of anemia. FibroGen is also currently pursuing the use of proprietary recombinant human type III collagens in synthetic corneas for treatment of corneal blindness. For more informaiton please visit www.fibrogen.com